Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

ClinicalTrials.gov ID: NCT05387707

Public ClinicalTrials.gov record NCT05387707. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 4:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Two-part, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate-to-Severe Pruritus in Adult Subjects With Atopic Dermatitis

Study identification

NCT ID
NCT05387707
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Cara Therapeutics, Inc.
Industry
Enrollment
287 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • TCS Cream Drug
  • Vehicle Cream Drug
  • difelikefalin 0.25 mg Drug
  • difelikefalin 0.5 mg Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 15, 2022
Primary completion
Feb 1, 2024
Completion
Feb 1, 2024
Last update posted
Feb 21, 2024

2022 – 2024

United States locations

U.S. sites
61
U.S. states
24
U.S. cities
59
Facility City State ZIP Site status
Cara Therapeutics Study Site Scottsdale Arizona 85260
Cara Therapeutics Study Site Fort Smith Arkansas 72916
Cara Therapeutics Study Site Rogers Arkansas 72758
Cara Therapeutics Study Site Fountain Valley California 92708
Cara Therapeutics Study Site Lomita California 90717
Cara Therapeutics Study Site Los Angeles California 90033
Cara Therapeutics Study Site Redwood City California 94063
Cara Therapeutics Study Site Sacramento California 95815
Cara Therapeutics Study Site San Diego California 92123
Cara Therapeutics Study Site 2 Santa Monica California 90404
Cara Therapeutics Study Site Santa Monica California 90404
Cara Therapeutics Study Site Valencia California 91355
Cara Therapeutics Study Site Denver Colorado 80210
Cara Therapeutics Study Site Brandon Florida 33511
Cara Therapeutics Study Site Coral Gables Florida 33134
Cara Therapeutics Study Site Delray Beach Florida 33484
Cara Therapeutics Study Site Hollywood Florida 33021
Cara Therapeutics Study Site North Miami Beach Florida 33162
Cara Therapeutics Study Site Orlando Florida 32819
Cara Therapeutics Study Site Saint Augustine Florida 32080
Cara Therapeutics Study Site St. Petersburg Florida 33709
Cara Therapeutics Study Site Sweetwater Florida 33172
Cara Therapeutics Study Site Tampa Florida 33607
Cara Therapeutics Study Site Marietta Georgia 30060
Cara Therapeutics Study Site Indianapolis Indiana 46250
Cara Therapeutics Study Site Plainfield Indiana 46168
Cara Therapeutics Study Site South Bend Indiana 46617
Cara Therapeutics Study Site Overland Park Kansas 66210
Cara Therapeutics Study Site Louisville Kentucky 40241
Cara Therapeutics Study Site Baton Rouge Louisiana 70809
Cara Therapeutics Study Site Houma Louisiana 70364
Cara Therapeutics Study Site Metairie Louisiana 70006
Cara Therapeutics Study Site New Orleans Louisiana 70115
Cara Therapeutics Study Site Rockville Maryland 20850
Cara Therapeutics Study Site Brighton Massachusetts 02135
Cara Therapeutics Study Site Auburn Hills Michigan 48326
Cara Therapeutics Study Site Clinton Township Michigan 48038
Cara Therapeutics Study Site Detroit Michigan 48202
Cara Therapeutics Study Site Waterford Michigan 48328
Cara Therapeutics Study Site Hackensack New Jersey 07601
Cara Therapeutics Study Site Huntersville North Carolina 28078
Cara Therapeutics Study Site Raleigh North Carolina 27617
Cara Therapeutics Study Site Athens Ohio 45701
Cara Therapeutics Study Site Bexley Ohio 43209
Cara Therapeutics Study Site Boardman Ohio 44512
Cara Therapeutics Study Site Oklahoma City Oklahoma 73118
Cara Therapeutics Study Site Oklahoma City Oklahoma 73170
Cara Therapeutics Study Site Philadelphia Pennsylvania 19103
Cara Therapeutics Study Site Plymouth Meeting Pennsylvania 19462
Cara Therapeutics Study Site Sugarloaf Pennsylvania 18249
Cara Therapeutics Study Site Charleston South Carolina 29407
Cara Therapeutics Study Site Knoxville Tennessee 37909
Cara Therapeutics Study Site Thompson's Station Tennessee 37179
Cara Therapeutics Study Site Arlington Texas 76011
Cara Therapeutics Study Site Austin Texas 78759
Cara Therapeutics Study Site Bellaire Texas 77401
Cara Therapeutics Study Site Houston Texas 77004
Cara Therapeutics Study Site San Antonio Texas 78209
Cara Therapeutics Study Site Springville Utah 84663
Cara Therapeutics Study Site Spokane Washington 99202
Cara Therapeutics Study Site Morgantown West Virginia 26505

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05387707, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 21, 2024 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05387707 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →